A4

Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Study. Tests the hypothesis that solanezumab, administered as an intravenous infusion at a dose of 400 mg every 4 weeks for 3 years, will slow cognitive decline as compared with placebo in subjects with preclinical AD.
Telephone
855-LOU-RUVO or (855-562-7886)
E-mail
Therapuetic Area
Cognitively Normal
Study Type
Clinical Trial
Compound
Solanezumab
Study Duration
168 weeks
Route of Admin
IV
Recruitment Status